Sheng W - Search Results

1

Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue directed against epidermal growth factor receptor.

Sheng W, Shang Y, Miao Q, Li Y, Zhen Y. Sheng W, et al. Anticancer Drugs. 2012 Apr;23(4):406-16. doi: 10.1097/CAD.0b013e32834f9801. Anticancer Drugs. 2012. PMID: 22205154

2

[Construction and screening of phage antibody libraries against epidermal growth factor receptor and soluble expression of single chain Fv].

Sheng WJ, Miao QF, Zhen YS. Sheng WJ, et al. Yao Xue Xue Bao. 2009 Jun;44(6):597-602. Yao Xue Xue Bao. 2009. PMID: 19806889 Chinese.

3

An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.

Sheng W, Shang Y, Li L, Zhen Y. Sheng W, et al. Anticancer Drugs. 2014 Jan;25(1):82-91. doi: 10.1097/CAD.0000000000000029. Anticancer Drugs. 2014. PMID: 24100279

4

A Gelatinases-targeting scFv-based Fusion Protein Shows Enhanced Antitumour Activity with Endostar against Hepatoma.

Gao R, Li L, Shang B, Zhao C, Sheng W, Li D. Gao R, et al. Among authors: sheng w. Basic Clin Pharmacol Toxicol. 2015 Aug;117(2):105-16. doi: 10.1111/bcpt.12379. Epub 2015 Feb 20. Basic Clin Pharmacol Toxicol. 2015. PMID: 25615234 Free article.

5

A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer.

Du Y, Shang BY, Sheng WJ, Zhang SH, Li Y, Miao QF, Zhen YS. Du Y, et al. Oncotarget. 2016 Sep 6;7(36):58418-58434. doi: 10.18632/oncotarget.11170. Oncotarget. 2016. PMID: 27517152 Free PMC article.

6

The recombinant EGFR/CD13 bi-targeted fusion protein induces apoptosis and blocks tube formation.

Sheng W, Gong J, Jiang M, Zhen Y. Sheng W, et al. Oncol Rep. 2017 Dec;38(6):3507-3514. doi: 10.3892/or.2017.6053. Epub 2017 Oct 23. Oncol Rep. 2017. PMID: 29130101

7

A new compound of thiophenylated pyridazinone IMB5043 showing potent antitumor efficacy through ATM-Chk2 pathway.

Gong J, Zheng Y, Wang Y, Sheng W, Li Y, Liu X, Si S, Shao R, Zhen Y. Gong J, et al. Among authors: sheng w. PLoS One. 2018 Feb 2;13(2):e0191984. doi: 10.1371/journal.pone.0191984. eCollection 2018. PLoS One. 2018. PMID: 29394294 Free PMC article.

8

A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer.

Wang X, Sheng W, Wang Y, Li L, Li Y, Zhang S, Liu X, Chen S, Zhen Y. Wang X, et al. Among authors: sheng w. Mol Pharm. 2018 Jun 4;15(6):2403-2412. doi: 10.1021/acs.molpharmaceut.8b00234. Epub 2018 May 23. Mol Pharm. 2018. PMID: 29757658

9

The ionophore antibiotic gramicidin A inhibits pancreatic cancer stem cells associated with CD47 down-regulation.

Wang RQ, Geng J, Sheng WJ, Liu XJ, Jiang M, Zhen YS. Wang RQ, et al. Cancer Cell Int. 2019 May 22;19:145. doi: 10.1186/s12935-019-0862-6. eCollection 2019. Cancer Cell Int. 2019. PMID: 31139022 Free PMC article.

10

An albumin‑binding domain and targeting peptide‑based recombinant protein and its enediyne‑integrated analogue exhibit directional delivery and potent inhibitory activity on pancreatic cancer with K‑ras mutation.

Sheng W, Geng J, Li L, Shang Y, Jiang M, Zhen Y. Sheng W, et al. Oncol Rep. 2020 Mar;43(3):851-863. doi: 10.3892/or.2020.7468. Epub 2020 Jan 15. Oncol Rep. 2020. PMID: 32020213 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,017 results

Search Page

Filters